Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11937966 | 0.89 | KDM4E (0.48) | KDM4EALOX15SMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL11937965 | 0.89 | KDM4E (0.51) | KDM4EALOX15SMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL3085714 | 0.86 | KDM4E (0.43) | KDM4EALOX15SMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL3079046 | 0.85 | — | — | |
| SCHEMBL3079251 | 0.82 | JMJD6 (0.53) | KDM4EALDH1A1HTT | |
| SCHEMBL11937963 | 0.79 | XDH (0.40) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL11937964 | 0.78 | NMT1 (0.40) | — | |
| SCHEMBL11938050 | 0.78 | — | — | |
| SCHEMBL11937524 | 0.77 | — | — | |
| SCHEMBL3219309 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2133331-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, CBR1 | KDM4E 1199/4885ALOX15 479/4885SMN1; SMN2 3153/4885 |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | XDH, DAO, DDO | KDM4E 1638/4885ALOX15 748/4885SMN1; SMN2 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.